This company has been marked as potentially delisted and may not be actively trading. NYSE:AMAM Ambrx Biopharma (AMAM) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Ambrx Biopharma Stock (NYSE:AMAM) 30 days 90 days 365 days Advanced Chart Get Ambrx Biopharma alerts:Sign Up Key Stats Today's Range$28.00▼$28.0050-Day Range$27.70▼$28.0052-Week Range$6.55▼$28.15VolumeN/AAverage Volume2.12 million shsMarket Capitalization$1.77 billionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Ambrx Biopharma Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing antibody drug conjugates (ADCs) and other engineered therapies to modulate the immune system. It focuses on portfolio of clinical and preclinical programs designed to optimize efficacy and safety in multiple cancer indications, including ARX517, its proprietary antibody-drug conjugate (ADC) targeting the prostate-specific membrane antigen (PSMA) and ARX788, its proprietary ADC targeting HER2. The company also has preclinical and clinical collaborations with multiple partners on drug candidates using Ambrx technology. The company was incorporated in 2003 and is headquartered in La Jolla, California. Read More Receive AMAM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Ambrx Biopharma and its competitors with MarketBeat's FREE daily newsletter. Email Address AMAM Stock News HeadlinesSunlands Technology (NYSE:STG) Stock Quotes, Forecast and News SummaryOctober 4, 2024 | benzinga.comCormorant Global Healthcare Master Fund, LP's Net WorthAugust 31, 2024 | benzinga.comThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, and he's been proven right time and time again. And now, while the media focuses on Tesla's "demise," he's uncovered an AI breakthrough that's about to make Elon's doubters eat their words yet again. According to his research, if you listen to the media and miss out on Elon's newest breakthrough, it's going to cost you the fortune of a lifetime.July 16 at 2:00 AM | Brownstone Research (Ad)14 Day AMERIBOR Average Rate (^AMBRX)May 24, 2024 | finance.yahoo.comLatest News for Johnson & Johnson Stock (NYSE:JNJ)April 5, 2024 | benzinga.comAmbrx Biopharma Inc.: Ambrx Shareholders Approve Acquisition by Johnson & JohnsonMarch 7, 2024 | finanznachrichten.deJohnson & Johnson Buys Ambrx Biopharma In $2 Bln Cash DealMarch 7, 2024 | markets.businessinsider.comAmbrx Shareholders Approve Acquisition by Johnson & JohnsonMarch 6, 2024 | globenewswire.comSee More Headlines AMAM Stock Analysis - Frequently Asked Questions When did Ambrx Biopharma IPO? Ambrx Biopharma (AMAM) raised $126 million in an IPO on Friday, June 18th 2021. The company issued 7,000,000 shares at $17.00-$19.00 per share. Goldman Sachs, BofA Securities and Cowen served as the underwriters for the IPO. What other stocks do shareholders of Ambrx Biopharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that Ambrx Biopharma investors own include NVIDIA (NVDA), Broadcom (AVGO), Arista Networks (ANET), Jabil (JBL), e.l.f. Beauty (ELF), Disc Medicine (IRON) and Adobe (ADBE). Company Calendar Today7/16/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNYSE:AMAM CIK1836056 Webambrx.com Phone858-875-2400FaxN/AEmployees87Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio13.28 Quick Ratio13.28 Sales & Book Value Annual Sales$7.40 million Price / Sales238.95 Cash FlowN/A Price / Cash FlowN/A Book Value$3.05 per share Price / Book9.18Miscellaneous Outstanding Shares63,150,000Free Float62,746,000Market Cap$1.77 billion OptionableOptionable Beta-1.92 Analysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free Report This page (NYSE:AMAM) was last updated on 7/16/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | Sponsored"Death Spiral" Threatening Your SavingsThe "Death Spiral" Threatening Your Savings But this time, it's not just Dalio ringing the alarm bells…GoldCo Precious Metals | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredSpecial gold investment soars 2,300% ... 5,090% ... 9,850%In my 54 years as an investor, I’ve seen my share of gold bull markets. But nothing comes close to the rall...Weiss Ratings | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredTrump’s biggest move, misreportedThe media and financial pundits are all misreading Trump’s actions. They think Trump wants to make Canada t...Porter & Company | SponsoredIs this secretive Asian company trying to take over Bitcoin?A mysterious Asian conglomerate is buying billions in Bitcoin — but one legendary trader says that’s the wrong...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ambrx Biopharma Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ambrx Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
